Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
CONTRAINDICATIONS:the product is not recommended for pregnant and breastfeeding women
Additionally, most ferroptosis modulators (e.g., ferrostatin-1 and triptolide) are evaluated in preclinical models of early AKI, but their efficacy in patients with established CKD (e.g., with tubulointerstitial fibrosis) is untestedwhether inhibiting ferroptosis can reverse or halt existing fibrosis, or only delay progression from AKI, remains unclear
10.1016/S0002-8223(00)00189-9 173
PRP, on the other hand, has a delayed onset of action
BPC-157 has been shown to stimulate the production of collagen and other key components essential for tissue repair